News
CSMG Technologies Forms Five Subsidiaries Under Live Tissue Connect, Inc.
Corpus Christi, TX, May 24, 2007 -- CSMG Technologies, Inc., (OTC Bulletin Board: CTUM - News) a technology management company, announced today it has formed five medical procedure specific subsidiaries wholly owned by its Live Tissue Connect, Inc. subsidiary.
The subsidiaries are being established for: Gynecology and General Surgery (GSG Medical Group), Orthopedics & Arthroscopy (Orthopedic Tissue Sciences), Colon Rectal Surgeries (Colorectal Connection Management), Pulmonary/lung (Pulmonary Sealing Sciences) and Urology (Urological Tissue Welding).
Donald S. Robbins, president and CEO of CSMG, said, "For some time we have been working toward isolating procedures and products for specific medical specializations. Now that we are completing final development of commercial instruments, design and electro surgery generator. With FDA filings immanent we are attracting interest from many qualified medical device companies and distributors who want to represent, license or market some area of the LTC product. We have thus far identified 12 specific procedure divisions but will establish the first five that are closest to product and market completion. Each of the LTC wholly owned subsidiaries represents a unique manufacturing, marketing or licensing opportunity under the LTC banner. This is truly a major commercial milestone for our company and I believe this approach adds considerable value to the company."
LTC's Frank D'Amelio added, "With a divisional, subsidiary structure we can leverage LTC's R&D developments across multiple medical disciplines. For example, the R&D effort that went into the development of a sealing device for gynecological arteries and veins can be leveraged into a similar acting device (though most likely different in shape/size) for Urological procedures. This structure allows potential partners to select surgical specialties where they have strong physician relationships and pre-existing distribution channels and discuss with LTC sales/marketing of LTC's unique bipolar products within such specialties."
CSMG owns the technology and exclusive world rights to the live tissue bonding device through Live Tissue Connect, Inc., a subsidiary corporation formed for the development and exploitation of the platform technology.
LTC expects to complete hand instruments, electrocautery generator and other electrosurgery components for the duct and vessel sealing system, meeting FDA and European CE Mark requirements, respectively. They also expect to start filing for approval of these devices with regulatory entities in early 2007.
About CSMG Technologies' Tissue Welding/Bonding Technology
The LTC tissue bonding / welding device is a platform technology that bonds and reconnects living soft biological tissue through fusion without the use of foreign matter in contrast with conventional wound closing devices such as sutures, staples, sealant, or glues.
Surgeons at 27 Ukraine hospitals and clinics are using the tissue welding/bonding technology in clinical trials. They have completed more than 7,000 human surgeries using more than 80 types of open and laparoscopic surgical procedures, demonstrating the technology is universal in its ability to repair soft biological tissue. These surgeries included lung, neuro-surgery, nasal septum, intestine, stomach, skin, gall bladder, liver, spleen, blood vessels, nerves, alba linea, uterus, bladder, gynecological, fallopian tube, ovary and testicles and dura-matter. Cosmetic surgeries conducted with this technology include breast reduction, breast implants, mastopexy and abdominoplasty. The procedure involves little or no scarring, while restoring the normal function of the body organ or tissue.
The technology was invented and developed at the internationally renowned E.O. Paton Institute of Electric Welding, National Academy of Sciences of Ukraine, Kiev, Ukraine, headed by Professor B.E. Paton. U.S., Australian, Canadian and European Union patents have been issued, and additional U.S. and foreign patents are pending, all owned by LTC.
About CSMG Technologies, Inc
LTC's surgical tissue bonding/welding device is a patented platform technology that bonds and reconnects human soft tissue through fusion, in contrast with conventional wound closing devices such as sutures, staples, sealant, or glues. LTC holds approximately 31 patents and pending patents in the U.S., Australia, Canada, European Union, Ukraine, and other countries.
For further information on CSMG Technologies and its various subsidiaries, please visit our website at www.csmgtechinternational.com.
Sign up to receive CSMG Technologies automated email press releases and other notifications: Please go to: www.csmgtechinternational.com/contact_information.html and fill-in information.
This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.